130 related articles for article (PubMed ID: 1397246)
41. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
[TBL] [Abstract][Full Text] [Related]
42. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Weber DM; Chen C; Niesvizky R; Wang M; Belch A; Stadtmauer EA; Siegel D; Borrello I; Rajkumar SV; Chanan-Khan AA; Lonial S; Yu Z; Patin J; Olesnyckyj M; Zeldis JB; Knight RD;
N Engl J Med; 2007 Nov; 357(21):2133-42. PubMed ID: 18032763
[TBL] [Abstract][Full Text] [Related]
43. Alpha-2a-interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma.
Montuoro A; De Rosa L; De Blasio A; Pacilli L; Petti N; De Laurenzi A
Br J Haematol; 1990 Nov; 76(3):365-8. PubMed ID: 2261347
[TBL] [Abstract][Full Text] [Related]
44. Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study.
Gertz MA; Kalish LA; Kyle RA; Hahn RG; Tormey DC; Oken MM
Am J Clin Oncol; 1995 Dec; 18(6):475-80. PubMed ID: 8526187
[TBL] [Abstract][Full Text] [Related]
45. alpha-Interferon for remission maintenance: preliminary report on the Southwest Oncology Group Study.
Salmon SE; Beckord J; Pugh RP; Barlogie B; Crowley J
Semin Oncol; 1991 Oct; 18(5 Suppl 7):33-6. PubMed ID: 1948127
[TBL] [Abstract][Full Text] [Related]
46. [Results of alternating treatment of multiple myeloma--cytostatics VBMCP and recombinant interferon alfa-2B].
Gola A; Usnarska-Zubkiewicz L; Wołowiec D; Urbaniak-Kujda D; Kotlarek-Haus S
Pol Arch Med Wewn; 1993 Aug; 90(2):134-41. PubMed ID: 8247946
[TBL] [Abstract][Full Text] [Related]
47. Phase II study of cyclophosphamide, interferon-alpha and betamethasone (CIB) as induction therapy for patients 60-75 years of age with multiple myeloma stages II and III.
Lundin J; Osterborg A; Björkholm M; Björkstrand B; Celsing F; Hjalmar V; Linder O; Luthman M; Merup M; Tidefelt U; Mellstedt H;
Hematol J; 2003; 4(4):248-52. PubMed ID: 12872149
[TBL] [Abstract][Full Text] [Related]
48. Combination of interferon and dexamethasone in refractory multiple myeloma.
San Miguel JF; Moro M; Bladé J; Guerras L; Hernandez J; Jimenez-Galindo R; Ortega F; Gonzalez M
Hematol Oncol; 1990; 8(4):185-9. PubMed ID: 2210687
[TBL] [Abstract][Full Text] [Related]
49. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
[TBL] [Abstract][Full Text] [Related]
50. 2',5'-Oligoadenylate synthetase levels in patients with multiple myeloma receiving maintenance therapy with interferon alpha 2b do not correlate with clinical response.
Millar BC; Bell JB
Br J Cancer; 1995 Dec; 72(6):1525-30. PubMed ID: 8519671
[TBL] [Abstract][Full Text] [Related]
51. A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group.
Peest D; Deicher H; Coldewey R; Leo R; Bartl R; Bartels H; Braun HJ; Fett W; Fischer JT; Göbel B
Eur J Cancer; 1995; 31A(2):146-51. PubMed ID: 7718318
[TBL] [Abstract][Full Text] [Related]
52. Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma.
Brugnatelli S; Riccardi A; Ucci G; Mora O; Barbarano L; Piva N; Piccinini L; Bergonzi C; De Paoli A; Di Stasi M; Rinaldi E; Trotti G; Petrini M; Ascari E
Br J Cancer; 1996 Mar; 73(6):794-7. PubMed ID: 8611382
[TBL] [Abstract][Full Text] [Related]
53. Dose escalation therapy in previously untreated patients with multiple myeloma following Z-Dex induction treatment.
Clark AD; Douglas KW; Mitchell LD; McQuaker IG; Parker AN; Tansey PJ; Franklin IM; Cook G
Br J Haematol; 2002 Jun; 117(3):605-12. PubMed ID: 12028028
[TBL] [Abstract][Full Text] [Related]
54. Dexamethasone, all trans retinoic acid and interferon alpha 2a in patients with refractory multiple myeloma.
Avilés A; Rosas A; Huerta-Guzmán J; Talavera A; Cleto S
Cancer Biother Radiopharm; 1999 Feb; 14(1):23-6. PubMed ID: 10850283
[TBL] [Abstract][Full Text] [Related]
55. Maintenance treatment with recombinant alpha interferon after autologous bone marrow transplantation for aggressive myeloma in first remission after conventional induction chemotherapy.
Attal M; Huguet F; Schlaifer D; Payen C; Lassoued S; Laroche M; Rossi JF; Fournie B; Mazieres B; Pris J
Bone Marrow Transplant; 1991 Aug; 8(2):125-8. PubMed ID: 1933053
[TBL] [Abstract][Full Text] [Related]
56. A randomised trial of cyclophosphamide with and without low dose alpha-interferon in the treatment of newly diagnosed myeloma.
Aitchison R; Williams A; Schey S; Newland AC
Leuk Lymphoma; 1993 Feb; 9(3):243-6. PubMed ID: 8471984
[TBL] [Abstract][Full Text] [Related]
57. Interferon-alpha as maintenance therapy in patients with multiple myeloma.
Schaar CG; Kluin-Nelemans HC; Te Marvelde C; le Cessie S; Breed WP; Fibbe WE; van Deijk WA; Fickers MM; Roozendaal KJ; Wijermans PW;
Ann Oncol; 2005 Apr; 16(4):634-9. PubMed ID: 15741226
[TBL] [Abstract][Full Text] [Related]
58. Interferon and multiple myeloma.
Lauta VM
Med Oncol; 1995 Mar; 12(1):63-9. PubMed ID: 8542250
[TBL] [Abstract][Full Text] [Related]
59. [Autologous transplantation of peripheral hematopoietic cells and subsequent maintenance therapy with interferon alpha or interferon alpha and dexamethasone in patients with multiple myeloma--results from the 4W randomized clinical trial of the Czech Myeloma Group].
Krejcí M; Hájek R; Scudla V; Bacovský J; Indrák K; Faber E; Koza V; Schützová M; Kuca B; Sumná E; Franková H; Lehanka F; Gumulec J; Stavarová Y; Rezek Z; Praskac P; Cahová S; Vránová M; Veprek K; Januska J; Kessler P; Pozdĕnová V; Walterová L; Stefánek I; Hausdorf P; Meluzínová I; Novosadová L; Lenícková S; Dusek L; Syobodník A; Králová E; Adam Z; Mayer J; Vorlícek J
Vnitr Lek; 2001 Sep; 47 Suppl 1():40-7. PubMed ID: 11693062
[TBL] [Abstract][Full Text] [Related]
60. Clinical stable systemic mastocytosis with interferon alpha-2b therapy.
Hübner C; Wedding U; Sträter J; Limberg B; Stremmel W
J Intern Med; 1997 Jun; 241(6):529-33. PubMed ID: 10497631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
